LAVACCHI, DANIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.375
EU - Europa 2.634
AS - Asia 2.422
SA - Sud America 200
Continente sconosciuto - Info sul continente non disponibili 109
AF - Africa 60
OC - Oceania 29
Totale 8.829
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.229
IT - Italia 941
RU - Federazione Russa 880
CN - Cina 683
SG - Singapore 678
HK - Hong Kong 287
VN - Vietnam 197
KR - Corea 187
IE - Irlanda 159
BR - Brasile 155
BD - Bangladesh 144
PL - Polonia 114
SE - Svezia 107
CA - Canada 92
FR - Francia 92
DE - Germania 87
FI - Finlandia 78
IN - India 61
JP - Giappone 44
NL - Olanda 42
GB - Regno Unito 40
ID - Indonesia 39
JO - Giordania 36
AU - Australia 29
MX - Messico 20
AT - Austria 19
CH - Svizzera 16
ES - Italia 15
IQ - Iraq 14
NG - Nigeria 13
PK - Pakistan 11
ZA - Sudafrica 11
AR - Argentina 10
UA - Ucraina 9
CI - Costa d'Avorio 8
AE - Emirati Arabi Uniti 7
CL - Cile 7
EC - Ecuador 7
JM - Giamaica 7
BJ - Benin 6
GR - Grecia 6
PE - Perù 6
PH - Filippine 6
VE - Venezuela 6
CO - Colombia 5
HN - Honduras 5
MA - Marocco 5
PT - Portogallo 5
AL - Albania 4
CR - Costa Rica 4
EG - Egitto 4
TR - Turchia 4
TT - Trinidad e Tobago 4
BB - Barbados 3
BE - Belgio 3
CZ - Repubblica Ceca 3
DZ - Algeria 3
KE - Kenya 3
LT - Lituania 3
OM - Oman 3
UZ - Uzbekistan 3
CU - Cuba 2
GT - Guatemala 2
KZ - Kazakistan 2
LV - Lettonia 2
NO - Norvegia 2
NP - Nepal 2
PR - Porto Rico 2
PY - Paraguay 2
RO - Romania 2
SA - Arabia Saudita 2
TW - Taiwan 2
UY - Uruguay 2
AZ - Azerbaigian 1
BH - Bahrain 1
BS - Bahamas 1
BZ - Belize 1
ET - Etiopia 1
GA - Gabon 1
GH - Ghana 1
HR - Croazia 1
IL - Israele 1
IR - Iran 1
KW - Kuwait 1
MD - Moldavia 1
MK - Macedonia 1
MM - Myanmar 1
MY - Malesia 1
NI - Nicaragua 1
PA - Panama 1
PS - Palestinian Territory 1
RS - Serbia 1
SC - Seychelles 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
SV - El Salvador 1
TG - Togo 1
TH - Thailandia 1
TJ - Tagikistan 1
TN - Tunisia 1
Totale 8.720
Salva come PNG Salva come JPEG
Città #
Santa Clara 757
Ashburn 520
Singapore 500
Hong Kong 259
Hefei 202
San Jose 196
Seoul 186
Milan 161
Dublin 157
Florence 120
Warsaw 110
Council Bluffs 105
Fairfield 92
Los Angeles 82
Beijing 80
Chandler 75
Moscow 62
Buffalo 61
The Dalles 58
Rome 56
Ho Chi Minh City 55
Dallas 52
Woodbridge 48
Munich 47
Lauterbourg 43
New York 43
Hanoi 42
Tokyo 39
Boardman 38
Seattle 37
Altamura 36
Houston 36
Helsinki 35
Jakarta 35
Lawrence 35
Cambridge 34
Shanghai 32
Toronto 32
Paris 29
Brescia 26
Melbourne 26
Wilmington 26
Ann Arbor 24
Lappeenranta 24
Kent 22
Naples 22
Chicago 21
Princeton 20
Bologna 18
Boston 18
Mumbai 18
Guangzhou 17
London 17
Turin 17
Vienna 17
Turku 16
Bengaluru 13
Haiphong 13
São Paulo 13
Abuja 12
Bern 12
Frankfurt am Main 12
Orem 12
Montreal 11
Genoa 10
Mexico City 10
Palermo 10
San Francisco 10
Figino 9
Tianjin 9
Abidjan 8
Dhaka 8
Johannesburg 8
Phoenix 8
Pune 8
Redondo Beach 8
Amsterdam 7
Atlanta 7
Bremen 7
North Charleston 7
San Diego 7
Brooklyn 6
Charlotte 6
Chennai 6
Cotonou 6
Curitiba 6
Dong Ket 6
Medford 6
Miano 6
Padua 6
Rio de Janeiro 6
Stockholm 6
Vũng Tàu 6
West Jordan 6
Ancona 5
Arezzo 5
Falls Church 5
Hillsboro 5
Las Vegas 5
Lisbon 5
Totale 5.283
Salva come PNG Salva come JPEG
Nome #
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. 291
Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions 275
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer 251
Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study 248
Aflibercept plus folfiri as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience 231
Metastatic intracranial solitary fibrous tumors/hemangiopericytomas: description of two cases with radically different behaviors and review of the literature 224
A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy 218
KRAS and NRAS mutation detection in circulating DNA from patients with metastatic colorectal cancer using BEAMing assay: Concordance with standard biopsy and clinical evaluation 214
Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy 208
Stable disease in a patient with metastatic leiomyosarcoma treated with trabectedin 207
Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality? 207
Evaluation of RAS mutational status through BEAMing assay to monitor disease progression of metastatic colorectal cancer: a case report 204
Association of systemic steroid treatment and outcome in patients treated with immune checkpoint inhibitors: A real-world analysis 203
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population 190
KRAS G12 isoforms exert influence over up-front treatments: A retrospective, multicenter, Italian analysis of the impact of first-line immune checkpoint inhibitors in an NSCLC real-life population 187
Added prognostic value of molecular imaging parameters over proliferation index in typical lung carcinoid: an [18F]FDG PET/CT and SSTR imaging study 186
Results of the observational prospective RealFLOT study 183
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 183
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: An early exploratory analysis of real-world data 178
Pathological complete response achieved with FLOT chemotherapy in two patients with MSI-H esophagogastric junction and gastric adenocarcinoma 173
Prognostic role of sodium levels in colorectal cancer patients receiving aflibercept plus FOLFIRI 168
KRAS-related miR-143 expression is associated with lymph node involvement and correlates with outcome in pancreatic adenocarcinoma patients 168
Vinorelbine in non-small cell lung cancer: Real-World data from a single institution experience 168
Long-term response of more than 9 years to regorafenib in a heavily pretreated patient with metastatic colorectal cancer 165
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination 164
Liquid biopsy in colorectal cancer: No longer young, but not yet old 162
Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience 161
Irinotecan-based chemotherapy in extrapulmonary neuroendocrine carcinomas: survival and safety data from a multicentric Italian experience 160
Immune checkpoint inhibitors in the treatment of renal cancer: Current state and future perspective 155
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 149
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer 147
Prognostic role of hERG1 Potassium Channels in Neuroendocrine Tumours of the Ileum and Pancreas 145
Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer 138
Early changes in circulating tumor DNA (ctDNA) predict treatment response in metastatic KRAS-mutated colorectal cancer (mCRC) patients 137
Tumor-Agnostic Treatment for Cancer: When How is Better than Where 136
Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer. 132
REBECA trial: A new piece of the evidence for bevacizumab in platinum-resistant recurrent ovarian cancer 131
Primary pleural epithelioid hemangioendothelioma: case report and review of the literature 130
Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge 129
Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study 122
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population 119
Everolimus as maintenance therapy in advanced neuroendocrine neoplasms: Results from the MAVERIC Phase II Trial (1499 WORDS MAIN TEXT) 117
Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis 106
MSI and EBV Positive Gastric Cancer's Subgroups and Their Link With Novel Immunotherapy 102
Treatment Strategy for Oligometastatic Gastric Cancer: Brief Considerations 95
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 94
The emerging HER2 landscape in colorectal cancer: the key to unveil the future treatment algorithm? 92
Electronic nicotine delivery systems (ENDS): not still ready to put on END 89
A Snapshot from the Italian Clinical Practice Regarding Efficacy and Utility Rate of Perioperative Chemotherapy in Muscle-invasive Bladder Cancer: The RealBLADDER Study 61
Ivosidenib for IDH1‐Mutant Intrahepatic Cholangiocarcinoma: Insights From a Multicenter Real‐World Study 56
Upfront Modified FOLFOXIRI Plus Panitumumab for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study 55
Beneath the surface of colorectal cancer: Unmasking the evolving nature of (Neo)RAS 53
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab 50
The impact of molecular alterations in patients with advanced biliary tract cancer receiving cisplatin, gemcitabine, and durvalumab: a large, real-life, worldwide population 48
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment 48
Radiomics on 177Lu-DOTATATE Posttreatment Scans: Feasibility, Preprocessing Optimization, and Planar-SPECT Comparison 48
Radiomics-based prediction of microsatellite instability in colorectal cancer: a non-invasive approach to treatment stratification 48
Immune checkpoint inhibitors in the first-line treatment of esophageal squamous cell carcinoma: Minireview for a big shift 46
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer 45
Prediction of Microsatellite Instability in Colorectal Cancer Using Two Internally Validated Radiomic Models 43
Transcriptomic analysis on pancreatic adenocarcinoma patients uncovers KRAS-mediated PPAR pathway alteration 36
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study 31
Navigating Disappearing Liver Metastases in Colorectal Cancer: A Review of Surgical and Non-Surgical Approaches 29
Durvalumab in Advanced Biliary Tract Cancer: Real‐World Data From a Large Cohort of Patients Across Multiple International Centers 24
Microbiome dysbiosis and KRAS-driven tumorigenesis in pancreatic cancer: implications for immune checkpoint inhibitors efficacy 23
A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC‐D Index 19
Impact of Antibiotic Therapy in Patients with Cholangiocarcinoma Treated with Chemoimmunotherapy 12
Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population 12
Totale 8.829
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.377
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.377
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022154 0 4 14 4 3 7 4 28 8 14 24 44
2022/2023571 33 108 30 36 20 101 78 48 61 14 20 22
2023/2024579 15 21 45 53 50 53 28 121 20 67 48 58
2024/20252.671 79 214 146 430 628 359 71 156 141 101 160 186
2025/20263.969 402 452 415 266 368 130 417 229 281 301 263 445
2026/2027420 300 120 0 0 0 0 0 0 0 0 0 0
Totale 8.829